Eli Lilly
4 articlesVisitors can use the page to follow sector analysis, sector exposure and fund ownership, review examples and see how public companies changes the way a product, rule, account or market signal should be interpreted.
Novo Nordisk Stock Drops After Heart Drug Trial Misses Key Target
Novo Nordisk shares tumbled after its heart drug Ziltivekimab failed a major late-stage trial, raising questions about the company's growth beyond weight-loss drugs and triggering a sharp market reaction
Eli Lilly's Soaring Stock Tests the 'Own, Don't Trade' Philosophy
Eli Lilly's stock has surged nearly 400% in five years, but with shares now above $1,150, investors face a key question: does the long-term case still hold, or is it time to rethink the classic buy-and-hold approach
UBS Hikes Eli Lilly Target as Prescription Data Clouds Outlook
UBS raised its price target for Eli Lilly to $1,425, outpacing other Wall Street banks, but new prescription data and high expectations ahead of earnings add risk for investors holding LLY shares into August
Biotech Stocks Outpace Tech as M&A Wave Reshapes 2026 Market
Biotech stocks are leading the market in 2026, fueled by a surge in acquisitions and a shift in regulatory policy. Investors are weighing whether the rally can continue as valuations climb and deal activity accelerates